NEWS
Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024
Agenus Inc. (Nasdaq: AGEN) presented promising data at the ESMO Congress for their Phase 1 study of botensilimab (BOT) and balstilimab (BAL) combination in refractory sarcomas. Key findings include:
- 23% overall response rate (ORR) in the full sarcoma cohort
- 21.7 months median duration of response (DOR)
- 69% 12-month overall survival (OS)
- 39% ORR in angiosarcoma subtype
- Manageable and reversible adverse event profile
The study involved 64 patients with relapsed/refractory sarcomas, with a median of 3 prior lines of therapy. The results suggest BOT/BAL could be a significant treatment option for patients with alternatives, particularly in 'cold' sarcomas like visceral angiosarcoma, leiomyosarcoma, and dedifferentiated liposarcoma.
- 23% overall response rate (ORR) in the full sarcoma cohort
- 21.7 months median duration of response (DOR)
- 69% 12-month overall survival (OS)
- 39% ORR in angiosarcoma subtype
- Manageable and reversible adverse event profile
The study involved 64 patients with relapsed/refractory sarcomas, with a median of 3 prior lines of therapy. The results suggest BOT/BAL could be a significant treatment option for patients with alternatives, particularly in 'cold' sarcomas like visceral angiosarcoma, leiomyosarcoma, and dedifferentiated liposarcoma.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2629Followers
107Following
28KVisitors
Follow